drugset
drugset / Trial / NCT05819853

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

NCT05819853 ↗

Phase 3 Recruiting 80 enrolled University of Colorado, Denver Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

Timeline

Start
2023-11-03
Primary completion
2028-02-01
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1.7 mg —

Indications

obesity disorder polycystic ovary syndrome